Beijing Wantai Biological Pharmacy Enterprise Co., Ltd.

XSSC:603392 Stock Report

Market Cap: CN¥92.3b

Beijing Wantai Biological Pharmacy Enterprise Past Earnings Performance

Past criteria checks 0/6

Beijing Wantai Biological Pharmacy Enterprise has been growing earnings at an average annual rate of 17.2%, while the Biotechs industry saw earnings growing at 7.6% annually. Revenues have been growing at an average rate of 21.7% per year.

Key information

17.2%

Earnings growth rate

16.4%

EPS growth rate

Biotechs Industry Growth11.3%
Revenue growth rate21.7%
Return on equity-2.3%
Net Margin-11.8%
Last Earnings Update30 Sep 2024

Recent past performance updates

Recent updates

Revenue & Expenses Breakdown

How Beijing Wantai Biological Pharmacy Enterprise makes and spends money. Based on latest reported earnings, on an LTM basis.

Earnings and Revenue History

XSSC:603392 Revenue, expenses and earnings (CNY Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 242,490-2949141,090
30 Jun 242,713-1949951,188
31 Mar 243,3771281,2141,165
31 Dec 235,5111,2481,9361,177
30 Sep 237,5042,6002,5411,524
30 Jun 239,4193,7453,1971,318
31 Mar 2310,9014,6503,5091,203
31 Dec 2211,1854,7363,5811,091
30 Sep 2210,8054,7773,455604
30 Jun 229,7163,9933,123708
31 Mar 228,0983,0632,779705
31 Dec 215,7502,0211,958677
30 Sep 214,3511,3981,554570
30 Jun 213,4751,1551,232382
31 Mar 212,8678961,011343
31 Dec 202,354677834309
30 Sep 201,953551704243
30 Jun 201,504368552223
31 Mar 201,244239516178
31 Dec 191,184209511164
30 Sep 191,096217472149
30 Jun 191,054269455141
31 Mar 191,007279428134
31 Dec 18983293421137
31 Dec 17950150362158
31 Dec 16844148350128
31 Dec 15681119269109
31 Dec 145961183220
31 Dec 13499802720

Quality Earnings: 603392 is currently unprofitable.

Growing Profit Margin: 603392 is currently unprofitable.

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Earnings Trend: 603392 is unprofitable, but has reduced losses over the past 5 years at a rate of 17.2% per year.

Accelerating Growth: Unable to compare 603392's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: 603392 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (1.3%).

Return on Equity

High ROE: 603392 has a negative Return on Equity (-2.34%), as it is currently unprofitable.

Return on Assets

Return on Capital Employed

Discover strong past performing companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/26 21:46
End of Day Share Price 2024/12/26 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Beijing Wantai Biological Pharmacy Enterprise Co., Ltd. is covered by 9 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Bo LiBofA Global Research
Zhizhong JingChina Merchants Securities Co. Ltd.
Wei SunChina Merchants Securities Co. Ltd.